(POH-lah-TOO-zoo-mab veh-DOH-tin)
This page contains brief information about polatuzumab vedotin-piiq and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
FDA label information for this drug is available at DailyMed.
Use in Cancer
Polatuzumab vedotin-piiq is approved to treat:
- Diffuse large B-cell lymphoma (DLBCL). It is used:
- With rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisone as the first treatment in adults who have low-intermediate to high-risk DLBCL or high-grade B-cell lymphoma.
- With bendamustine hydrochloride and rituximab in adults whose DLBCL has come back or has not gotten better after at least two other therapies.
Polatuzumab vedotin-piiq is also being studied in the treatment of other types of cancer.
More About Polatuzumab Vedotin-piiq
Definition from the NCI Drug Dictionary – Detailed scientific definition and other names for this drug.
More About Polatuzumab Vedotin-piiq – A lay language summary of important information about this drug that may include the following:
- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.
Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Polatuzumab Vedotin-piiq – Check for trials from NCI’s list of cancer clinical trials now accepting patients.
